Sarcoplasmic reticulum-associated cAMP phosphodiesterase activity was examined in microsomes prepared from the left ventricular myocardium of eight heart transplant recipients with end-stage idiopathic dilated cardiomyopathy and six unmatched organ donors with normal cardiac function. At cAMP concentrations < 1.0 MM, sarcoplasmic reticulum-associated cAMP phosphodiesterase activity was functionally homogeneous. cAMP phosphodiesterase activity was inhibited competitively by cGMP (K; = 0.031±0.008 MM) and the cilostamide derivative OPC 3911 (K; = 0.018±0.004 gM), but was essentially insensitive to rolipram. V.,,. and K. were 781.7±109.2 nmol/mg per min and 0.188±0.031,MM, respectively, in microsomes prepared from nonfailing hearts and 793.9±68.9 nmol/ mg per min and 0.150±0.027MgM in microsomes prepared from failing hearts. Microsomes prepared from nonfailing and failing hearts did not differ with respect to either the ratio of cAMP phosphodiesterase activity to ATP-dependent Ca2" accumulation activity or the sensitivity of cAMP phosphodiesterase activity to inhibition by OPC 3911. These data suggest that the diminished inotropic efficacy of phosphodiesterase inhibitors in failing human hearts does not result from changes in the level, kinetic properties, or pharmacologic sensitivity of sarcoplasmic reticulum-associated cAMP phosphodiesterase activity. (J. Clin. Invest. 1991.88:15-19.)
Introduction
Certain drugs that inhibit cAMP hydrolysis by cyclic nucleotide phosphodiesterases increase myocardial contractility, and there is interest in the potential usefulness ofsuch agents in the treatment of heart failure. Five distinct families of cyclic nucleotide phosphodiesterases have been identified and characterized (1) . Studies in animals suggest that the inotropic efficacy of phosphodiesterase inhibitors is most closely related to their ability to inhibit the activity of enzymes belonging to the cGMP-inhibited cAMP phosphodiesterase family (cGI PDE', often referred to as PDE III), which are characterized by their high affinity for cAMP, insensitivity to rolipram, and susceptibility to competitive inhibition by low concentrations of cGMP, cilostamide derivatives, and some of the newer inotropic agents such as milrinone, amrinone, and enoximone (2) (3) (4) (5) (6) (7) (8) .
In addition, the association of cGI PDE with the sarcoplasmic reticulum appears to be an important determinant of the inotropic efficacy of these agents. In dog and rhesus monkey, whose cGI PDE activity is localized to the sarcoplasmic reticulum, cGI PDE inhibitors are very effective as inotropic agents. These inhibitors are much less effective inotropic agents in hamster, guinea pig, and rat, whose cGI PDE activity is predominantly cytoplasmic (9, 10) .
Studies of tension development in muscle strips obtained from normal and failing human hearts have demonstrated a decreased inotropic response to phosphodiesterase inhibitors in the latter (11, 12) . As suggested in these reports, this diminished augmentation of tension development may reflect impaired cAMP generation. It is also plausible, however, that alterations in sarcoplasmic reticulum-associated cGI PDE activity contributed to the diminished response. To investigate this possibility, we examined and compared the characteristics of sarcoplasmic reticulum-associated cAMPphosphodiesterase activity in microsomes prepared from normal and failing human hearts.
Methods
Procurement ofhuman cardiac tissue. Left ventricular free wall myocardium was obtained from the excised failing hearts ofeight transplant recipients (age 49.1±5.4 yr) with class IV heart failure resulting from idiopathic dilated cardiomyopathy, and the nonfailing hearts of six unmatched organ donors (age 40.3±6.7 yr). The sarcolemmal fl-adrenergic receptor density, measured as previously described (13, 14), was 99.8±14.4 fmol/mg in the nonfailing hearts and 49.8±5.0 fmol/mg in the failing hearts (P < 0.01).
Preparation ofhuman cardiac microsomes. Microsomes were prepared from left ventricular free wall myocardial tissue as previously described (15) , save that the pH of the buffer solutions used in the homogenization and differential sedimentation steps was adjusted to 6.0 rather than 7.0. This modification increased the specific cAMP phosphodiesterase activity without decreasing total cAMP phosphodiesterase activity.
Measurement ofcAMPphosphodiesterase activity. The method for measuring cAMP phosphodiesterase activity was adapted from the protocol described by Kincaid and Manganiello (16 Miscellaneous. Protein was measured according to the method of Bradford using bovine serum albumin as a standard (19) . Lipids were extracted from microsomes by the method of Bligh and Dyer (20) , and the phosphorus contents ofthe extracts were quantified by the method of Chen et al. (21) . Oxalate-supported, ATP-dependent Ca2`accumulation by human cardiac microsomes was measured as previously described (15) in the presence of0.102 M KCl, 5 .05 mM MgCl2, 1.0 mM EGTA, 0.99 mM CaCl2, 5.0 mM oxalic acid, 5.0 mM NaN3, 0.5 mM ryanodine, 5.0 mM ATP, and 20 mM MOPS (pH = 7.05, 37°C). The free Ca2+ concentration was calculated to be 5.0,uM (18) . OPC 3911 was supplied by Otsuka Chemicals, Ltd., Osaka, Japan.
Results
Sarcoplasmic reticulum-associated cAMP phosphodiesterase activity was measured under standard conditions in microsomes prepared from left ventricular free wall myocardium obtained from failing human hearts. In Fig. 1 , cAMP phosphodiesterase activity is plotted as a function of cAMP concentration in double reciprocal form. The linearity of the double reciprocal plot indicates that the cAMP phosphodiesterase activity associated with the sarcoplasmic reticulum follows the Michaelis-Menton steady-state model, with Vm,, = 533±18 pmol/mg-min and Km = 0.133±0.013 MM in this preparation.
The high affinity for cAMP suggested that the cAMP phosphodiesterase activity associated with human cardiac sarcoplasmic reticulum reflected the presence of either cGMP-or rolipram-inhibited phosphodiesterases. To distinguish between these possibilities, the effects of specific inhibitors of these phosphodiesterase families were examined (Fig. 2) previous studies (15, 22) , this activity was similar in preparations from normal and failing hearts. These findings confirmed that microsomes prepared from normal and failing hearts were comparable with respect to sarcoplasmic reticulum content and activity. Values for Vm,, and Km for cAMP phosphodiesterase activity in these preparations are listed in Table II . No differences between preparations from normal and failing hearts were observed with respect to either parameter. In addition, the ratio of cAMP phosphodiesterase activity to Ca2" accumulation activity was determined in each preparation. The preparations from normal and failing hearts did not differ with respect to this ratio.
It remained possible that physiologically significant differences between normal and failing hearts with respect to sarcoplasmic reticulum-associated cAMP phosphodiesterase activity were present but were not detected under the chosen assay conditions. For this reason, sarcoplasmic reticulum-associated cAMP phosphodiesterase activity in microsomes prepared from normal and failing hearts was reexamined under conditions selected to more closely resemble the intracellular environment. Specifically, cAMP phosphodiesterase activity was assayed in the presence of 105 mM KC1, 0.8 mM Mg2", 0.2 gM Ca2", and 5 mM ATP at pH 7.05 (370C). The free Ca2" concentration in cardiac myocytes varies throughout the cardiac cycle; the value of 0.2 ,M was chosen because the most well-characterized local substrate for cAMP-dependent protein kinase is phospholamban, and the effects of phospholamban phosphorylation on Ca2" accumulation by human cardiac sarcoplasmic 
Discussion
The steady-state kinetic parameters ofcAMP hydrolysis in cardiac microsomes and its sensitivity to inhibition by cGMP and OPC 3911 suggest that the cAMP phosphodiesterase activity associated with human left ventricular sarcoplasmic reticulum belongs to the cGI PDE family. The linearity of the double reciprocal plots and the relative insensitivity to inhibition by rolipram suggest additionally that the activity is functionally homogeneous, and that cGI PDE is the predominant (if not sole) species responsible for cAMP hydrolysis at submicromolar concentrations of cAMP in human cardiac sarcoplasmic reticulum. Similar findings-have been reported in rabbit and canine preparations (7, 9) . The values for Km for cAMP and Ki for inhibition ofcAMP phosphodiesterase activity by cGMP in our preparations are similar to values reported for highly purified bovine cardiac (Km = 0.15 MM, Ki = 0.06 AM, reference 6) and human platelet (Km = 0.18 MM, Ki = 0.035 MM, reference 24) forms of cGI PDE, as well to those reported for less highly purified preparations ofthe human cardiac enzyme (Km = 0.14 MM in reference 25 and 0.36 MM in reference 26).
Our comparison of sarcoplasmic reticulum-associated cGI PDE activity in microsomes prepared from normal and failing human hearts revealed no significant differences with respect Human Cardiac Sarcoplasmic Reticulum-associated Phosphodiesterase 17 to V,, and Km for cAMP or the ratio of cGI PDE activity to ATP-dependent Ca2l transport. Furthermore, we found no difference between the two groups with respect to susceptibility of sarcoplasmic reticulum-associated cGI PDE activity to inhibition by OPC 391 1. Based on these results, the decreased inotropic efficacy of phosphodiesterase inhibitors in tissue from failing human hearts cannot be ascribed to intrinsic alterations in sarcoplasmic-reticulum associated cGI PDE activity. It remains possible that normal and failing hearts differ with respect to the regulation of phosphodiesterase activity. In intact cell preparations, human platelet and rat adipocyte cGI PDE's are phosphorylated and activated by agents that increase intracellular cAMP concentrations, and phosphorylation of the human platelet enzyme by cAMP-dependent protein kinase in vitro results in stimulation ofcAMP phosphodiesterase activity (27, 28) . To date, stimulation of phosphodiesterase activity by phosphorylation has not been observed in cardiac preparations, but further study of this issue seems warranted.
In addition, the low Ki for inhibition of cAMP phosphodiesterase activity by cGMP raises the possibility that cGMP is involved in the regulation of the enzyme in vivo. The competitive nature of this inhibition suggests that this regulation may be particularly significant in failing human myocardium, where intracellular cAMP concentrations may be low due to j3, receptor downregulation and partial uncoupling off2 receptors from adenylate cyclase (13, 29) .
It is also possible that sarcoplasmic reticulum structure is altered in failing human myocardium. As noted earlier, studies in animals suggest that the inotropic efficacy of phosphodiesterase inhibitors may depend upon the association of the enzyme with the sarcoplasmic reticulum. cAMP metabolism in cardiac myocytes appears to be compartmentalized (30) , and the association of cGI PDE with the sarcoplasmic reticulum may provide a mechanism for the local regulation ofcAMP-dependent protein kinase activation and the selective phosphorylation ofphospholamban. This phosphorylation results in stimulation of Ca2" accumulation by human cardiac sarcoplasmic reticulum in vitro (22) , and myocardial contraction and relaxation may be modulated via the effects of this stimulation on intracellular [Ca2+] transients. Alterations affecting the proximity of cGI PDE to phospholamban in failing myocardium could result in dissociation of phosphodiesterase inhibition from its effects on sarcoplasmic reticulum Ca2' handling, and the diminished inotropic efficacy of phosphodiesterase inhibitors in failing myocardium might be explained on this basis.
Finally, the possibility that interactions with other intracellular pools of cGI PDE are involved in the inotropic effects of phosphodiesterase inhibitors in humans must be considered. The presence of cGI PDE activity in the cytoplasmic fractions of human myocardium has been reported (26), but whether this activity was present in the cytoplasm in vivo is unclear: the tissue used in the study referred to was obtained post-mortem, and the cGI PDE activity identified as 'cytoplasmic' may have been dissociated from the sarcoplasmic reticulum artifactually during the preparation (we were able to dissociate a significant fraction of cGI PDE activity from the sarcoplasmic reticulum in our preparations simply by freezing and thawing). Determining the intracellular distribution of cGI PDE in human myocardium in vivo using ultrastructural methods may be especially useful in this regard.
